AIC
ACHN

Ameritas Investment Company’s Achillion Pharmaceuticals ACHN Stock Holding History

Ameritas Investment Company’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,317
Closed -$2K – 2020
2018
Q4 		$2K Buy
+1,317
New +$3.72K ﹤0.01% 1392

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameritas Investment Company's ACHN Position: Q1 2019 in Review

Ameritas Investment Company sold out of Achillion Pharmaceuticals (ACHN) in Q1 2019, closing a stake of 1,317 shares — an estimated $2K sold.

Ameritas Investment Company first reported a position in ACHN in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

  • Ameritas Investment Company reported no remaining Achillion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 1,317 Achillion Pharmaceuticals shares in Q1 2019, an estimated $2K.
  • Ameritas Investment Company first reported a position in Achillion Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Ameritas Investment Company's Achillion Pharmaceuticals position peaked at $2K in Q4 2018.
  • 110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.